Literature DB >> 18190444

Acral myxoinflammatory fibroblastic sarcoma: case series and immunohistochemical analysis.

Carrie L Kovarik1, Terry Barrett, Aaron Auerbach, David S Cassarino.   

Abstract

BACKGROUND: Acral myxoinflammatory fibroblastic sarcoma (AMFS) is a rare, low-grade neoplasm most often occurring on the extremities of adults. It consists of mixed inflammatory infiltrates with nodules of epithelioid, spindled and bizarre-appearing cells within a fibrosclerotic-to-myxoid stroma. AMFS frequently recurs, but only rarely metastasizes.
MATERIALS AND METHODS: A retrospective analysis of all cases of AMFS seen in the past 4 years from the Stanford University Laboratory of Surgical Pathology and collaborating institutions was performed. We sought to better characterize the clinicopathologic characteristics of this rare tumor. Immunohistochemical stains, including CD34, epithelial membrane antigen (EMA), epidermal growth factor receptor (EGFR), CD117, CD163, Ki67 and p53, were also performed.
RESULTS: Eighteen cases were analyzed, and clinical information was available on 13 of them. The mean age at diagnosis was 48 years old, 10/13 (77%) occurred on the distal extremities and diameter of the lesions ranged from 1.0 to 10.0 cm. Treatment included wide local or radical excision and local recurrences were not reported. Many of the lesions were multinodular. Histologic characteristics included the presence of fibrosclerotic and myxoid stroma, sheets of spindled to round epithelioid cells, Reed-Sternberg or virocyte-like cells, lipoblast-like cells and rare mitotic figures. In most cases, CD34, EGFR and CD163 were diffusely positive. EMA and CD117 were weakly positive in some cases. Ki67 labeled < 10% of cells, and staining with P53 was variable.
CONCLUSIONS: Because AMFS may be mistaken for lymphoma, infection or tumors with higher metastatic potential, correct diagnosis is important to avoid unnecessary procedures and allow for proper clinical management. EGFR positivity suggests possible therapeutic use in aggressive cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18190444     DOI: 10.1111/j.1600-0560.2007.00791.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

1.  Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome.

Authors:  William B Laskin; John F Fetsch; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

2.  CD34 negative superficial acral fibromyxoma: A rare case report.

Authors:  Reza M Robati; Sahar Dadkhahfar; Azadeh Rakhshan
Journal:  Indian Dermatol Online J       Date:  2017 Jan-Feb

3.  Immunohistochemical detection of STAT6, CD34, CD99 and BCL-2 for diagnosing solitary fibrous tumors/hemangiopericytomas.

Authors:  Yunan Han; Qingfu Zhang; Xinmiao Yu; Xu Han; Huan Wang; Yingying Xu; Xueshan Qiu; Feng Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 4.  A case of lung metastasis in myxoinflammatory fibroblastic sarcoma: analytical review of one hundred and thirty eight cases.

Authors:  Raffaele Lombardi; Elio Jovine; Nicola Zanini; Maria Cristina Salone; Marco Gambarotti; Alberto Righi; Alba Balladelli; Marco Colangeli; Michele Rocca
Journal:  Int Orthop       Date:  2013-09-06       Impact factor: 3.075

5.  Acral myxoinflammatory fibroblastic sarcoma: A case report and literature review.

Authors:  Andrew G Silver; Richard C Baynosa; Raman C Mahabir; Wei Z Wang; William A Zamboni; Kayvan T Khiabani
Journal:  Can J Plast Surg       Date:  2013

6.  Large cervicothoracic myxoinflammatory fibroblastic sarcoma with brachial plexus invasion: A case report and literature review.

Authors:  Xiaotian Jia; Jianyun Yang; Lin Chen; Cong Yu
Journal:  Oncol Lett       Date:  2016-07-08       Impact factor: 2.967

7.  Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases.

Authors:  David Suster; Michael Michal; Huiya Huang; Shira Ronen; Stephanie Springborn; Maria Debiec-Rychter; Steven D Billings; John R Goldblum; Brian P Rubin; Michal Michal; Saul Suster; A Craig Mackinnon
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

8.  Giant myxoinflammatory fibroblastic sarcoma with bone invasion: a very rare clinical entity and literature review.

Authors:  Guray Togral; Murat Arikan; Elif Aktas; Safak Gungor
Journal:  Chin J Cancer       Date:  2014-07-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.